Cannabinoid Biosciences, Inc. (“CBDZ”) is a biopharmaceutical company, which intends to engage in the discovery, development and commercialization of cures and novel therapeutics from proprietary cannabinoid, cannabidiol, endocannabinoids, phytocannabinoids, and synthetic cannabinoids product platform suitable for specific treatments in a broad range of disease areas.
Our business is divided into four segments namely:
1. Biopharmaceutical Research and Development;
2. Investments into legal-cannabis businesses and deriving value from rollup/consolidation events that leads to IPO in US or Canada;
3. Financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses; and
4. Professional services including top-level financial reporting, Accounting
Two of our business units are in flux and have investment opportunities that we want to capitalize upon immediately:
• Rollup and Consolidation: Investments into legal-cannabis businesses and deriving value from rollup/consolidation events that leads to IPO in US or Canada; and
• Financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses.
CBDZ is raising $125 million with Reg A+ ($50 million) and Reg. D 506 (c) ($75 million). The Company had filed the required filings with the SEC and is waiting for their go-ahead for the Reg. A+. CBDZ has agreed to rollup 10 dispensaries with $54 million in annual revenue. These rollup will IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE) via Reg. A+, which is already filed with the SEC. Once our Reg A+ is qualified, CBDZ will be listed on the NASDAQ or NYSE. A $1,000 invested at this ground floor could fetch up to $21,500 based on what the NASDAQ and NYSE market-participants sale-to-market cap multiples for rollup/consolidated Cannabis business.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 3699 Wilshire Blvd.,,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cbdxfund.com
- HQ
- Los Angeles, CA
- Competitors
- Cancer Genetics, Inc., The Cannabinoid Research Institute, IACM _ International Alliance for Cannabinoid Medicines, GCG Patrice & Associates, Cannabinoid Research & Development Global (CRDG) Network, Research In Color Foundation, Behind HRIS Lines ™, The Pain Clinic Malta, Cannabinoid Regulations, BAUM TENPERS INSTITUTE.
Cannabinoid Biosciences, Inc. Questions
Cannabinoid Biosciences, Inc.'s website is cbdxfund.com
Cannabinoid Biosciences, Inc.'s LinkedIn profile is https://www.linkedin.com/company/cbdxfund
Cannabinoid Biosciences, Inc. has
4 employees.
View email and phone details for 4
employees at Cannabinoid Biosciences, Inc..
Cannabinoid Biosciences, Inc.'s industry is
Biotechnology Research
Cannabinoid Biosciences, Inc.'s top competitors are
Cancer Genetics, Inc.,
The Cannabinoid Research Institute,
Iacm _ International Alliance For Cannabinoid Medicines,
Gcg Patrice & Associates,
Cannabinoid Research & Development Global (Crdg) Network,
Research In Color Foundation,
Behind Hris Lines ™,
The Pain Clinic Malta,
Cannabinoid Regulations,
Baum Tenpers Institute.
Cannabinoid Biosciences, Inc.'s categories are Biotechnology Research
Cannabinoid Biosciences, Inc.'s founding year is 2014
